title: Phase II study of three days' fractionated dosage of ifosfamide, epirubicin and cisplatin in small cell lung cancer.
authors.affiliation: Division of Medical Oncology, Faculty of Medicine, Chiang Mai University, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Thongprasert
authors.forename: N
authors.initials: N
authors.lastname: Phromwas
authors.forename: B
authors.initials: B
authors.lastname: Atikachi
authors.forename: K
authors.initials: K
authors.lastname: Jiemsripong
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D015251:Epirubicin; D002945:Cisplatin; D007069:Ifosfamide